2ALNY : 27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...
Fintel on MSN20h
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation
Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...
BioSpace1d
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Redburn Atlantic
Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...
Alnylam price target raised to $345 from $300 at Stifel
Stifel raised the firm’s price target on Alnylam (ALNY) to $345 from $300 and keeps a Buy rating on the shares following the recent FDA ...
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a ...
Alnylam initiated with a Buy at Redburn Atlantic
Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to Overweight at JPMorgan Chase & Co.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...
Business Wire3d
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors
Shares of Charles River Laboratories International Inc. slipped 3.01% to $145.99 Tuesday, on what proved to be an all-around ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip
Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...
Le Lézard8h
Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products
Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high ...